Peter P Toth

Summary

Publications

  1. doi request reprint An update on the benefits and risks of rosuvastatin therapy
    Peter P Toth
    Director of Preventive Cardiology, CGH Medical Center, Sterling, IL Professor of Clinical Family and Community Medicine, University of Illinois School of Medicine, Peoria, IL
    Postgrad Med 126:7-17. 2014
  2. doi request reprint Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease
    Peter P Toth
    CGH Medical Center, 101 East Miller Road, Sterling, IL 61081, USA College of Medicine, University of Illinois, Peoria, IL, USA Electronic address
    J Clin Lipidol 8:107-16. 2014
  3. doi request reprint High-density lipoproteins: a consensus statement from the National Lipid Association
    Peter P Toth
    CGH Medical Center, Sterling, IL 61081, USA University of Illinois School of Medicine, Peoria, IL, USA Michigan State University College of Osteopathic Medicine, East Lansing, MI, USA Electronic address
    J Clin Lipidol 7:484-525. 2013
  4. doi request reprint Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants
    Peter P Toth
    Preventive Cardiology, CGH Medical Center, Sterling, IL61081, USA
    Postgrad Med 125:155-61. 2013
  5. doi request reprint Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia
    Peter P Toth
    CGH Medical Center, Sterling, IL 61081, USA
    J Clin Lipidol 7:S6-10. 2013
  6. pmc The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus
    Peter P Toth
    CGH Medical Center, 101 East Miller Rd, Sterling, IL, 61081, USA
    Cardiovasc Diabetol 11:109. 2012
  7. doi request reprint Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, IL, USA
    J Clin Lipidol 6:325-30. 2012
  8. doi request reprint Epicardial steatosis, insulin resistance, and coronary artery disease
    Peter P Toth
    CGH Medical Center, 101 East Miller Road, Sterling, IL 61081, USA
    Heart Fail Clin 8:671-8. 2012
  9. ncbi request reprint Effective management of the type 2 diabetes patient with cardiovascular and renal disease: secondary prevention strategies after a myocardial infarction
    Peter P Toth
    Preventive Cardiology, CGH Medical Center, Sterling, IL 61081, USA
    Curr Diabetes Rev 8:219-28. 2012
  10. doi request reprint Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction
    Peter P Toth
    CGH Medical Center and University of Illinois College of Medicine, 101 East Miller Road, Sterling, IL 61081, USA
    J Clin Lipidol 6:180-91. 2012

Detail Information

Publications49

  1. doi request reprint An update on the benefits and risks of rosuvastatin therapy
    Peter P Toth
    Director of Preventive Cardiology, CGH Medical Center, Sterling, IL Professor of Clinical Family and Community Medicine, University of Illinois School of Medicine, Peoria, IL
    Postgrad Med 126:7-17. 2014
    ..Publications selected for inclusion in this review were published from January 1, 2010 to December 31, 2013, and provide new information pertaining to the efficacy and safety of rosuvastatin. ..
  2. doi request reprint Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease
    Peter P Toth
    CGH Medical Center, 101 East Miller Road, Sterling, IL 61081, USA College of Medicine, University of Illinois, Peoria, IL, USA Electronic address
    J Clin Lipidol 8:107-16. 2014
    ....
  3. doi request reprint High-density lipoproteins: a consensus statement from the National Lipid Association
    Peter P Toth
    CGH Medical Center, Sterling, IL 61081, USA University of Illinois School of Medicine, Peoria, IL, USA Michigan State University College of Osteopathic Medicine, East Lansing, MI, USA Electronic address
    J Clin Lipidol 7:484-525. 2013
    ..On the basis of an enormous amount of basic scientific and clinical investigation, a considerable number of reasons support the need to continue to investigate the therapeutic effect of modulating HDL structure and function. ..
  4. doi request reprint Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants
    Peter P Toth
    Preventive Cardiology, CGH Medical Center, Sterling, IL61081, USA
    Postgrad Med 125:155-61. 2013
    ..The pharmacology, clinical efficacy, and potential adverse effects of these drugs in patients with atrial fibrillation are reviewed herein...
  5. doi request reprint Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia
    Peter P Toth
    CGH Medical Center, Sterling, IL 61081, USA
    J Clin Lipidol 7:S6-10. 2013
    ..Available data regarding the efficacy, safety and tolerability of mipomersen, including results at up to 104 weeks of therapy, support the use of mipomersen for the treatment of FH...
  6. pmc The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus
    Peter P Toth
    CGH Medical Center, 101 East Miller Rd, Sterling, IL, 61081, USA
    Cardiovasc Diabetol 11:109. 2012
    ....
  7. doi request reprint Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, IL, USA
    J Clin Lipidol 6:325-30. 2012
    ..Despite national lipid guidelines, the prevalence of these abnormal lipid parameters alone or in combination (mixed dyslipidemia) is not well recognized...
  8. doi request reprint Epicardial steatosis, insulin resistance, and coronary artery disease
    Peter P Toth
    CGH Medical Center, 101 East Miller Road, Sterling, IL 61081, USA
    Heart Fail Clin 8:671-8. 2012
    ..This article explores such associations from biochemical and structural standpoints, focusing on changes in epicardial adiposity...
  9. ncbi request reprint Effective management of the type 2 diabetes patient with cardiovascular and renal disease: secondary prevention strategies after a myocardial infarction
    Peter P Toth
    Preventive Cardiology, CGH Medical Center, Sterling, IL 61081, USA
    Curr Diabetes Rev 8:219-28. 2012
    ..This comprehensive approach helps to maximize both the likelihood of reaching treatment targets for blood glucose, blood pressure, and serum lipids, and reducing the long-term risk of diabetes-related morbidity and mortality...
  10. doi request reprint Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction
    Peter P Toth
    CGH Medical Center and University of Illinois College of Medicine, 101 East Miller Road, Sterling, IL 61081, USA
    J Clin Lipidol 6:180-91. 2012
    ..Recent trends suggest a decreased use of ezetimibe/simvastatin combination and coadministered ezetimibe plus statin therapies...
  11. pmc Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois College of Medicine, Peoria, CGH Medical Center, 101 East Miller Road, Sterling, IL 61081, USA
    Vasc Health Risk Manag 8:39-44. 2012
    ....
  12. doi request reprint Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    Curr Med Res Opin 25:1355-63. 2009
    ..Niacin and fibrates have been shown in clinical trials to be effective as adjunctive therapy for these lipid abnormalities...
  13. ncbi request reprint SPARCL: the glimmer of statins for stroke risk reduction
    Annemarie Armani
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 9:347-51. 2007
    ..Patients with a history of stroke should be treated much more aggressively with statin therapy in order to more optimally reduce risk for stroke recurrence...
  14. ncbi request reprint When high is low: raising low levels of high-density lipoprotein cholesterol
    Peter P Toth
    Preventive Cardiology, Sterling Rock Falls Clinic, Ltd, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Cardiol Rep 10:488-96. 2008
    ....
  15. pmc Ezetimibe therapy: mechanism of action and clinical update
    Binh An P Phan
    Division of Cardiology, Loyola University Medical Center, Maywood, IL, USA
    Vasc Health Risk Manag 8:415-27. 2012
    ....
  16. ncbi request reprint The role of statins in managing diabetic dyslipidemia
    Peter P Toth
    Sterling Rock Falls Clinic, Ltd, Sterling, Illinois, USA
    J Fam Pract 59:S23-9. 2010
    ..Strategies must be implemented to improve the quality of care for these patients who are at high risk for a primary or secondary CV event...
  17. doi request reprint Novel therapies for increasing serum levels of HDL
    Peter P Toth
    Sterling Rock Falls Clinic, Ltd, 101 East Miller Road, Sterling, IL 61081, USA
    Endocrinol Metab Clin North Am 38:151-70. 2009
    ..This article discusses the development of newer treatments targeted at raising HDL-C and HDL particle numbers to reduce residual risk in patients at risk for CHD...
  18. doi request reprint Antisense therapy and emerging applications for the management of dyslipidemia
    Peter P Toth
    Department of Preventive Cardiology, CGH Medical Center, Sterling, IL, USA
    J Clin Lipidol 5:441-9. 2011
    ..One alternative approach, antisense therapy, may offer an effective and well-tolerated option for patients not satisfactorily responsive to or intolerant to standard pharmacologic dyslipidemia therapies...
  19. ncbi request reprint Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 11:71-9. 2009
    ..A variety of prospective, placebo-controlled clinical trials have also shown that these agents significantly impact risk for multiple cardiovascular end points...
  20. ncbi request reprint An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Commentary
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, USA
    J Fam Pract 58:S41-3. 2009
    ..Unfortunately, for most patients, CHD is not diagnosed during routine screening. Rather, the diagnosis of CHD often is made only after symptoms occur, or when the patient is evaluated incidentally for another health problem...
  21. ncbi request reprint High-dose statin therapy: benefits and safety in aggressive lipid lowering
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, Illinois, USA
    J Fam Pract 57:S29-36. 2008
  22. doi request reprint High-density lipoproteins: marker of cardiovascular risk and therapeutic target
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    J Clin Lipidol 4:359-64. 2010
    ..These drugs exploit a diverse range of mechanisms with potential for beneficially impacting the development and progression of atherosclerotic disease...
  23. ncbi request reprint Cholesterol absorption blockade with ezetimibe
    Peter P Toth
    Director of Preventive Cardiology, Sterling Rock Falls Clinic, Illinois, University of Illnois School of Medicine, Peoria, 61081, USA
    Curr Drug Targets Cardiovasc Haematol Disord 5:455-62. 2005
    ..Ezetimibe is indicated in the management of hyperlipidemia, familial hypercholesterolemia, and sitosterolemia and significantly increases the percentage of patients able to reach their lipid-lowering goals...
  24. doi request reprint The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, IL, USA
    Postgrad Med 121:59-72. 2009
    ..Patients with a history of transient ischemic attack or stroke should not receive prasugrel + aspirin because of increased risk of events...
  25. doi request reprint Fibrate therapy in the management of diabetic dyslipidemia: there is no ACCORD to be found
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 12:331-5. 2010
    ..The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial suggests that the addition of fenofibrate to ongoing statin therapy in patients with type 2 diabetes mellitus offers limited benefit...
  26. pmc Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, IL, USA
    Cardiovasc Diabetol 8:26. 2009
    ..To evaluate real-world pharmacologic treatment of mixed dyslipidemia in patients with diabetes mellitus (DM)...
  27. ncbi request reprint Lipid therapy utilization rates in a managed-care mixed dyslipidemia population
    Peter P Toth
    Sterling Rock Falls Clinic, 101 E Miller Road, Sterling IL 61081, USA, University of Illinois College of Medicine Peoria, IL, USA and Southern Illinois University School of Medicine Springfield, Illinois
    J Clin Lipidol 2:365-74. 2008
    ..National clinical treatment guidelines recommend pharmacologic treatment in addition to therapeutic lifestyle modifications in patients with mixed dyslipidemia and multiple risk factors for coronary heart disease (CHD)...
  28. ncbi request reprint Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, Illinois, USA
    Expert Opin Pharmacother 6:131-9. 2005
    ..This combination increases the likelihood of therapeutic success in patients with dyslipidaemia...
  29. doi request reprint Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs
    Peter P Toth
    Preventive Cardiology, Sterling Rock Falls Clinic, Sterling, Illinois 61081, USA
    Drugs 70:1363-79. 2010
    ..Fibrates, niacin and omega-3 fish oils are efficacious therapies for reducing serum triglycerides. Combinations of these drugs are frequently required for normalizing mixed forms of dyslipidaemia...
  30. ncbi request reprint The CARDS trial: diabetic patients dealt a winning hand
    Annemarie Armani
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 8:429-32. 2006
    ..Benefit emerged within 1 year of initiating therapy...
  31. ncbi request reprint New insights in the treatment of dyslipidemia: a focus on cardiovascular event reduction and the anti-atherosclerotic effects of atorvastatin
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    Curr Atheroscler Rep 7:335-43. 2005
    ..Additional studies with atorvastatin are underway to further explore the extent to which statins can provide cardiovascular benefits...
  32. doi request reprint CETP Inhibition: does the future look promising?
    Peter P Toth
    Director of Preventive Cardiology, Sterling Rock Falls Clinic, IL 61081, USA
    Curr Cardiol Rep 13:559-65. 2011
    ....
  33. doi request reprint Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Cardiol Rep 12:481-7. 2010
    ....
  34. ncbi request reprint Thienopyridine therapy and risk for cardiovascular events in secondary prevention
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    Curr Atheroscler Rep 11:364-70. 2009
    ....
  35. doi request reprint Practical management of anticoagulants in family medicine after orthopedic surgery
    Peter P Toth
    CGH Medical Center, Sterling, IL 61081, USA
    Postgrad Med 124:206-14. 2012
    ..This article examines the clinical evidence for benefits of the new oral anticoagulants, discusses caveats regarding their appropriate use, and provides some guidance regarding bleeding management with these agents...
  36. ncbi request reprint Cardiology patient page. The "good cholesterol": high-density lipoprotein
    Peter P Toth
    University of Illinois School of Medicine, Peoria, USA
    Circulation 111:e89-91. 2005
  37. ncbi request reprint Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 9:81-8. 2007
    ..Combining new HDL cholesterol-elevating agents with existing LDL cholesterol-lowering agents may improve the cardiovascular risk reductions currently attainable...
  38. doi request reprint Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Expert Rev Cardiovasc Ther 8:425-38. 2010
    ..In addition to substantially inhibiting Lp-PLA(2), darapladib reduces the progression of the necrotic core volume of coronary artery atheromatous plaque...
  39. ncbi request reprint Should we target HDL cholesterol level in lowering cardiovascular risk?
    Peter P Toth
    Preventive Cardiology, Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    Pol Arch Med Wewn 119:667-72. 2009
    ....
  40. ncbi request reprint Expert commentary: gastrointestinally active lipid-lowering drug safety
    Peter P Toth
    Sterling Rock Falls Clinic, Ltd, Sterling, Illinois 61081, USA
    Am J Cardiol 99:56C-58C. 2007
  41. ncbi request reprint Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, USA
    Clin Ther 26:1355-67. 2004
    ..Low back pain is a leading reason for primary care visits. Many treatment options are available, but some lack scientific support...
  42. doi request reprint Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    Postgrad Med 123:46-53. 2011
    ..6% to 0.8%, with a safety profile comparable with placebo. This article provides a review of linagliptin clinical data for primary care physicians treating patients with type 2 diabetes mellitus...
  43. doi request reprint Is the future of statins aligned with new novel lipid modulation therapies?
    Binh An P Phan
    Loyola University Chicago Stritch School of Medicine, Loyola University Medical Center, 2160 S First Avenue, Bldg 110, Rm 6221, Maywood, IL 60153, USA
    Curr Atheroscler Rep 15:300. 2013
    ..Although statin therapy is the current recommended primary treatment for dyslipidemia, emerging novel agents may become adjuvant therapies in the treatment of atherosclerotic heart disease...
  44. ncbi request reprint An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Atherosclerosis: the underlying disease
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, USA
    J Fam Pract 58:S19-25. 2009
    ..The text and figures that follow will review new developments in our understanding of the pathogenesis of atherosclerosis and new ways that changes in atherosclerotic plaque size and volume can be measured...
  45. doi request reprint Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapy
    Peter P Toth
    Department of Preventive Cardiology, Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    J Clin Hypertens (Greenwich) 13:42-51. 2011
    ..This review also identifies some potentially important differences in the mechanism of action between ARBs and angiotensin-converting enzyme inhibitors that may have clinical significance in the management of vascular diseases...
  46. ncbi request reprint Therapeutic interventions targeted at the augmentation of reverse cholesterol transport
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, Illinois 61081, USA
    Curr Opin Cardiol 19:374-9. 2004
    ..This review summarizes the pathway of RCT and the currently available means by which investigators are attempting to modulate HDL levels and increase rates of RCT...
  47. ncbi request reprint High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, Illinois 61081 1252, USA
    Am J Cardiol 96:50K-58K; discussion 34K-35K. 2005
    ....
  48. doi request reprint Drug safety evaluation of rosuvastatin
    Peter P Toth
    University of Illinois College of Medicine, CGH Medical Center, Sterling, Peoria, IL, USA
    Expert Opin Drug Saf 10:969-86. 2011
    ..Rosuvastatin has been exhaustively evaluated in the setting of a broad variety of dyslipidemias and cardiovascular disease states in clinical trials encompassed within the GALAXY program...
  49. doi request reprint Clinical characterization and molecular mechanisms of statin myopathy
    Peter P Toth
    Sterling Rock Falls Clinic, Ltd, 101 East Miller Road, Sterling, IL 61081, USA
    Expert Rev Cardiovasc Ther 6:955-69. 2008
    ....